Are Genpharmasec Ltd latest results good or bad?

Feb 09 2026 07:15 PM IST
share
Share Via
Genpharmasec Ltd's latest results show strong year-on-year growth in net profit and revenue, but significant sequential declines and reliance on non-operating income raise concerns about sustainability and operational consistency, indicating challenges ahead.
Genpharmasec Ltd's latest financial results reveal a complex picture of growth and operational challenges. In Q2 FY26, the company reported a net profit of ₹1.22 crore, which reflects a significant year-on-year increase of 269.70%. However, this positive trend is overshadowed by a sequential decline in net profit, which saw a dramatic drop of over 500% compared to the previous quarter.
Revenue for the same quarter reached ₹12.04 crore, marking an impressive year-on-year growth of 131.54%. Yet, this growth was not consistent, as revenue declined by 14.06% from ₹14.01 crore in Q1 FY26. This volatility raises concerns about the sustainability of the company's revenue streams. The operating margin, excluding other income, improved to 7.81% from 4.04% in the previous year, indicating some operational leverage. However, it remains below the 8.61% achieved in Q4 FY25, highlighting ongoing inconsistencies in operational performance. Additionally, the average return on equity (ROE) stands at a low 1.84%, suggesting challenges in capital efficiency and overall business economics. The company's reliance on other income is notable, as it constituted approximately 42% of pre-tax profits in Q2 FY26, raising questions about the quality and sustainability of earnings derived from core operations. Furthermore, the financial performance has been marked by extreme volatility, with significant fluctuations in profitability across recent quarters. Genpharmasec's valuation has also seen an adjustment in its evaluation, reflecting growing market recognition of the company's challenges. The stock trades at a price-to-earnings ratio of 35x, which appears high given the weak return metrics and inconsistent profitability, suggesting potential mispricing relative to its fundamentals. Overall, while Genpharmasec Ltd shows some positive year-on-year growth, the underlying operational inconsistencies, reliance on non-operating income, and low return metrics indicate significant challenges that may affect its future performance.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News